Bottom line
FHLC vs HIAHX: the short answer
FHLC (Fidelity MSCI Health Care Index ETF) and HIAHX (Hartford Healthcare Hls Fund) share a meaningful slice of their top holdings — about 71% by weight.
But FHLC is far broader, holding 337 positions to 79 for HIAHX, so beyond the top names it adds exposure HIAHX doesn't have.
FHLC is cheaper at 0.084% vs 0.94% — a difference of $86 a year per $10,000 invested.
Over five years, FHLC returned +7.2% a year vs +3.5% for HIAHX (reporting dates differ).
Updated Nov 19, 2026
FHLC vs HIAHX side by side
| FHLC | HIAHX | |
|---|---|---|
| Type | ETF | Mutual fund |
| Fund family | Fidelity | Hartford |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.084% | 0.94% |
| Annual cost per $10k | $8.4 | $94 |
| 10-yr cost on $10k (prospectus) | $108 | $1,155 |
| Max front load | None | — |
| 12b-1 fee | 0% | 0% |
| 1-yr return | +2.6% | +16.1% |
| 5-yr return (annualized) | +7.2% | +3.5% |
| 10-yr return (annualized) | +8.8% | +7.9% |
| Best quarter | +16.4% | +21.0% |
| Worst quarter | −13.1% | −15.6% |
| Net assets (fund) | $3.3B | $112.4M |
| Number of holdings | 337 | 79 |
| Portfolio turnover | 3% | 5% |
| Returns as of | Nov 30, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | FHLC | HIAHX | Difference |
|---|---|---|---|
| 2024 | +2.6% | +0.4% | +2.2% |
| 2023 | +2.5% | +4.1% | −1.6% |
| 2022 | −5.5% | −11.2% | +5.8% |
| 2021 | +20.4% | +10.0% | +10.4% |
| 2020 | +18.1% | +23.1% | −5.0% |
| 2019 | +21.9% | +34.0% | −12.0% |
| 2018 | +5.5% | −2.7% | +8.2% |
| 2017 | +23.3% | +22.3% | +1.1% |
| 2016 | −3.3% | −8.4% | +5.1% |
Source: Fund prospectus bar charts
Holdings overlap
19 of FHLC's top 25 holdings also appear in HIAHX's top 25.
| Holding | FHLC | HIAHX |
|---|---|---|
| Eli Lilly & Co | 13.35% | 12.47% |
| Johnson & Johnson | 8.93% | 6.63% |
| AbbVie Inc | 6.42% | 3.43% |
| UnitedHealth Group Inc | 5.44% | 4.72% |
| Merck & Co Inc | 4.66% | 6.60% |
| Thermo Fisher Scientific Inc | 3.09% | 1.64% |
| Abbott Laboratories | 2.66% | 2.10% |
| CVS Health Corp | 1.92% | 2.93% |
| Intuitive Surgical Inc | 1.82% | 2.99% |
| Danaher Corp | 1.80% | 2.65% |
| Vertex Pharmaceuticals Inc | 1.76% | 2.69% |
| Stryker Corp | 1.62% | 1.17% |
| Medtronic PLC | 1.59% | 1.02% |
| Elevance Health Inc | 1.19% | 2.96% |
| Regeneron Pharmaceuticals Inc | 1.15% | 1.52% |
Source: SEC Form N-PORT
FHLC top 10
- Eli Lilly & Co — 13.35%
- Johnson & Johnson — 8.93%
- AbbVie Inc — 6.42%
- UnitedHealth Group Inc — 5.44%
- Merck & Co Inc — 4.66%
- Thermo Fisher Scientific Inc — 3.09%
- Amgen Inc — 3.00%
- Abbott Laboratories — 2.66%
- Gilead Sciences Inc — 2.34%
- Pfizer Inc — 2.06%
HIAHX top 10
- Eli Lilly & Co — 12.47%
- Johnson & Johnson — 6.63%
- Merck & Co Inc — 6.60%
- UnitedHealth Group Inc — 4.72%
- AbbVie Inc — 3.43%
- Intuitive Surgical Inc — 2.99%
- Elevance Health Inc — 2.96%
- CVS Health Corp — 2.93%
- Vertex Pharmaceuticals Inc — 2.69%
- Danaher Corp — 2.65%
FAQ
What is the difference between FHLC and HIAHX?
Which is cheaper, FHLC or HIAHX?
Should I own both FHLC and HIAHX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.